The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more: dctd.cancer.gov/about/news-e... @swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP

On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma

#FindingsFriday: New insights from the CHAARTED trial, presented at #ASTRO25 - the APUC-6 signature (six androgen production/uptake & conversion genes) may help stratify metastatic #ProstateCancer & refine treatment response. Learn more: bit.ly/43SaV5t #PrecisionMedicine

ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch

#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa

The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S

After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...

DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch @swog.org

The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website. Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc

Phase 3 #ClinicalTrial EA8231 is now enrolling! This study is exploring a new treatment approach for patients with treatment-refractory locally-advanced or metastatic #UrothelialCancer. Learn more: bit.ly/ea8231-study... #TargetedTherapy

Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈

Thank you to the exceptional presenters and panelists who helped make the Fall 2025 Comis #TranslationalScience Symposium a success: Drs. Jon Steingrimsson, @rhubbbstat.bsky.social, Paul Catalano, Walter Witschey, @jordanberlin5.bsky.social, & Mary Lou Smith!

The Comis #TranslationalScience Symposium continues with talks by Dr. Paul Catalano of @danafarber.bsky.social @hsph.harvard.edu & Dr. Walter Witschey @pennmedicine.bsky.social. #AI #imaging

First up: talks from Dr. Jon Steingrimsson & Dr. @rhubbbstat.bsky.social, both of @brownbiostatistics.bsky.social, on #AI, #MachineLearning, & #RealWorldData in cancer #ClinicalTrials. More to come!

Group Co-Chair Dr. Mitch Schnall of @pennmedicine.bsky.social kicks off the Fall 2025 Robert L. Comis Translational Science Symposium, focused on #AI, #RealWorldData, and alternative approaches to phase 2 and 3 therapeutic questions. #EAOnc

The Robert L. Comis, MD Translational Science Symposium on Approaches Using #AI and Other Electronic Methods in #ClinicalTrials is underway. Join us in Salon E, 5th Floor! #EAOnc #CancerResearch

Congratulations to the Fall 2025 Edith Peterson Mitchell, MD Travel Scholars! #CancerResearch #ClinicalTrials #EAOnc

Congratulations to the early-career researchers selected to present at our annual Young Investigator Symposium! 🩻🩺📈#EAOnc

#Immunotherapy after surgery shows potential in preventing spread of aggressive skin cancer. STAMP (EA6174) results at #ESMO25 by Dr. Janice Mehnert of NYU Langone’s Perlmutter Cancer Center. Largest study to date to evaluate pembrolizumab as adjuvant therapy for #MerkelCellCarcinoma bit.ly/4hgQrJg

The #EAOnc Fall 2025 Group Meeting officially begins today! Looking forward to seeing you in Philadelphia. Check in at the registration desk on the 5th floor before heading to your first session. 🩺🩻📈

You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: bit.ly/apollo-trial #pancsm

Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration. Learn more: bit.ly/4pRWiZy

We congratulate Dr. Anthony Letai on his appointment as NCI Director. His deep scientific expertise & reputation as a collaborative leader make him an excellent choice to drive progress against #cancer. We look forward to working with him! #CancerResearch #ClinicalTrials

Today is #WorldCancerResearchDay! Catch up on the latest @eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch

Today is the 2025 Rally for Medical Research! #RallyForNIH unites patients, survivors, researchers & advocates urging Congress to make National Institutes of Health funding a national priority. Join us in calling for sustained, robust NIH support. Important info➡️ rallyformedicalresearch.org

#NIH research is the basis for countless treatments and cures for patients battling life-threatening and chronic conditions. Join today’s #RallyMedRes & urge Congress to support robust, sustained funding for NIH. Tools & resources here: rallyformedicalresearch.org #FundNIH

ICYMI: Check out our round-up of recently published @eaonc.bsky.social research results. More here ➡️ bit.ly/aug25research #EAOnc

September is #ProstateCancerAwarenessMonth 💙. This month, we’re spotlighting EA8191/INDICATE, a #ClinicalTrial treating #ProstateCancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging. More here: bit.ly/indicate-trial

More good news from Washington: Last week the House Labor-HHS Subcommittee advanced its FY26 spending bill, increasing both NCI & NIH funding and rejecting the proposed cuts. Thank you for working to prioritize #CancerResearch, patients, and survivors. Read more: bit.ly/4n3sYNN

In our August newsletter, the co-chairs spotlight an open letter to Congress from the National Clinical Trials Network Cooperative Group Chairs, detailing its significant contributions to patient welfare. Read their editorial and the full letter here: bit.ly/41x0VO5 #CancerResearch #ClinicalTrials

The EA3211 clinical study is testing a potential new treatment for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: bit.ly/ea3211-study #hncsm

Submit an Abstract for the 2025 Young Investigator Symposium by Thursday, 9/11! 🩻 We are now accepting research abstracts from early-career investigators interested in presenting your research as part of the upcoming Fall 2025 Group Meeting. More: bit.ly/yis-fall25 #EAOnc

Trial Activation: EA2234/STOPGAP II, led by Dr. Maheswari Senthil of UCI Health, is a randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis. More: bit.ly/ea2234-stopg... #StomachCancer

Trial Activation: EAA241, led by Dr. Amany Keruakous of @wellstarhealth.bsky.social, is a randomized phase II trial comparing daratumumab-bortezomib-dexamethasone vs cyclophosphamide-bortezomib dexamethasone in newly diagnosed #MultipleMyeloma. For more info: bit.ly/EAA241

ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research #ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma

An encouraging update from Washington re: support for #CancerResearch funding! Good news for the entire cancer research community--but most importantly for patients.

#FindingsFriday: Did you know we publish patient-friendly, 1-2 page summaries of the results of many of our #ClinicalTrials? View them here: bit.ly/trial-summar... #CancerResearch #ClinicalTrials

#RareCancers like #sarcoma can be difficult to study--but cooperative research groups like ours make it possible. This #SarcomaAwarenessMonth, learn about EA7211/STRASS 2, an international trial in #RetroperitonealSarcoma: bit.ly/EA7211STRASS... @eortc.org

Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM

Do you have an aggressive B-cell #Lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in #ClinicalTrial EA4231. More info here: bit.ly/EA4231 #lymsm

Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials

Today is #GBMDay! 🧠 Learn about EAF223/GABLE, a #Glioblastoma study testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: bit.ly/gable-trial

Did you know July is #SarcomaAwarenessMonth? Take a moment to read our trial spotlight on EA7211/STRASS 2. This #clinicaltrial is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma. More: bit.ly/EA7211STRASS...

Now Enrolling: CLEAR Study for Operable Non-Small Cell Lung Cancer blog-ecog-acrin.org/now-enrollin...

In #ClinicalTrial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients with advanced undifferentiated pleomorphic sarcoma (UPS). For more information: bit.ly/EA7222 #sarcomaawareness

Congratulations to Dr. Petros Grivas on receiving the 2025 Young Investigator Award from @eaonc.bsky.social! He's recognized for a distinguished record of innovative research, outstanding clinical practice, and unwavering dedication to advancing the field of genitourinary oncology.

In the latest edition of our advocacy blog, Glenn Sykes, #KidneyCancer survivor and #CancerResearch advocate, writes about the importance of a strong patient-oncologist bond. In honor of #NationalCancerSurvivorsMonth, read more: bit.ly/44Vobb4

Petros Grivas of @fredhutch.bsky.social, Joan Schiller of @ouchinternational.bsky.social, and Zachary Avigan receive ECOG-ACRIN (‪@eaonc.bsky.social‬) 2025 scientific leadership, mentorship awards https://cancerletter.com/in-brief/20250613_8b/

The Stanford Cancer Institute has been an @eaonc.bsky.social Cancer Research Group Main Member Institution since 1985. This membership reflects our leadership in national cancer research, helping shape and conduct NCI-sponsored clinical trials nationwide.  blog-ecog-acrin.org/institution-...